Top

Published in:

Open Access 01-12-2014 | Research

Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications

Authors: Laura van Dussen, Marieke Biegstraaten, Marcel GW Dijkgraaf, Carla EM Hollak

Published in: Orphanet Journal of Rare Diseases | Issue 1/2014

Abstract

Long-term complications and associated conditions of type 1 Gaucher Disease (GD) can include splenectomy, bone complications, pulmonary hypertension, Parkinson disease and malignancies. Enzyme replacement therapy (ERT) reverses cytopenia and reduces organomegaly. To study the effects of ERT on long-term complications and associated conditions, the course of Gaucher disease was modelled.

The cohort consisted of all diagnosed GD patients in the Netherlands. Mutually exclusive disease states were defined as ‘asymptomatic’, ‘signs/symptoms’, ‘recovery’, ‘splenectomy’, ‘bone complication’, ‘multiple complications’ and ‘malignancy’. A natural history (NH) cohort was delineated based upon historical data on Dutch patients before ERT was available. Cumulative incidence curves were composed for progression from each disease state to the next. Two scenarios were applied for the ERT cohort: time to complications was calculated from A. start of ERT; B. entering the previous disease state.

Median time for the development of signs and/or symptoms was 30.1 years (N = 73). In the NH cohort (N = 42), 9% had developed a bone complication after 10 years in the signs/symptoms phase, while 21% had undergone a splenectomy. In the ERT cohort (N = 29 (A), N = 28 (B)), 12% (A) or 4% (B) had developed a bone complication after 10 years in this phase and no patient was splenectomized. No patients in the NH cohort recovered, compared to 50% in the ERT cohort after 3.6 years (N = 28 (A)) or 22.4 years (N = 27 (B)) of treatment. Median time from a first to a second complication was 11 years in the NH cohort (N = 31), whereas 16 respectively 14 percent had developed a second complication after 10 years in the ERT cohort (N = 17, scenario A/B). Fourteen percent (scenario A/B) developed an associated malignancy after 10 years in the phase ‘multiple complications’ (N = 23). Associated malignancies occurred almost exclusively in advanced disease stages, therefore it is suggested that ERT reduces their incidence

Long-term ERT for GD can reduce the incidence of splenectomy and bone complications. As ERT prevents progression to more advanced stages of GD it will most likely result in a reduction of associated malignancies.

Available only for authorised users

Grabowski GA, Petsko GA, Kolodny EH: Gaucher Disease. The Online Metabolic & Molecular Bases of Inherited Disease. Edited by: Valle D, Beaudet AL, Vogelstein B, Kinzler K, Antonarakis SE, Ballabio A. New York: McGraw-Hill, 2010.

Kolodny EH, Ullman MD, Mankin HJ, Raghavan SS, Topol J, Sullivan JL: Phenotypic manifestations of Gaucher disease: clinical features in 48 biochemically verified type 1 patients and comment on type 2 patients. ProgClinBiolRes. 1982, 95: 33-65.

de Fost M, vom Dahl S, Weverling GJ, Brill N, Brett S, Haussinger D, Hollak CE: Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis. 2006, 36: 53-58. 10.1016/j.bcmd.2005.08.004.CrossRefPubMed

Shiran A, Brenner B, Laor A, Tatarsky I: Increased risk of cancer in patients with Gaucher disease. Cancer. 1993, 72: 219-224. 10.1002/1097-0142(19930701)72:1<219::AID-CNCR2820720139>3.0.CO;2-Y.CrossRefPubMed

Neudorfer O, Giladi N, Elstein D, Abrahamov A, Turezkite T, Aghai E, Reches A, Bembi B, Zimran A: Occurrence of Parkinson’s syndrome in type I Gaucher disease. QJM. 1996, 89: 691-694. 10.1093/qjmed/89.9.691.CrossRefPubMed

Tayebi N, Walker J, Stubblefield B, Orvisky E, LaMarca ME, Wong K, Rosenbaum H, Schiffmann R, Bembi B, Sidransky E: Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?. Mol Genet Metab. 2003, 79: 104-109. 10.1016/S1096-7192(03)00071-4.CrossRefPubMed

Mistry PK, Sirrs S, Chan A, Pritzker MR, Duffy TP, Grace ME, Meeker DP, Goldman ME: Pulmonary hypertension in type 1 Gaucher’s disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab. 2002, 77: 91-98. 10.1016/S1096-7192(02)00122-1.CrossRefPubMed

Roberts WC, Fredrickson DS: Gaucher’s disease of the lung causing severe pulmonary hypertension with associated acute recurrent pericarditis. Circulation. 1967, 35: 783-789. 10.1161/01.CIR.35.4.783.CrossRefPubMed

Arends M, van Dussen L, Biegstraaten M, Hollak CE: Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature. Br J Haematol. 2013, 161: 832-842. 10.1111/bjh.12335.CrossRefPubMed

10.

Bohte AE, van Dussen L, Akkerman EM, Nederveen AJ, Sinkus R, Jansen PL, Stoker J, Hollak CE: Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage. PLoS One. 2013, 8: e57507-10.1371/journal.pone.0057507.CrossRefPubMedPubMedCentral

11.

Fleshner PR, Aufses AH, Grabowski GA, Elias R: A 27-year experience with splenectomy for Gaucher’s disease. Am J Surg. 1991, 161: 69-75. 10.1016/0002-9610(91)90363-I.CrossRefPubMed

12.

Lo SM, Stein P, Mullaly S, Bar M, Jain D, Pastores GM, Mistry PK: Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types–correlation with genotype and phenotype. Am J Hematol. 2010, 85: 340-345.PubMedPubMedCentral

13.

Lukina E, Watman N, Arreguin EA, Dragosky M, Iastrebner M, Rosenbaum H, Phillips M, Pastores GM, Kamath RS, Rosenthal DI, Kaper M, Singh T, Puga AC, Peterschmitt MJ: Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood. 2010, 116: 4095-4098. 10.1182/blood-2010-06-293902.CrossRefPubMedPubMedCentral

14.

McEachern KA, Fung J, Komarnitsky S, Siegel CS, Chuang WL, Hutto E, Shayman JA, Grabowski GA, Aerts JM, Cheng SH, Copeland DP, Marshall J: A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab. 2007, 91: 259-267. 10.1016/j.ymgme.2007.04.001.CrossRefPubMed

15.

Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE: Replacement therapy for inherited enzyme deficiency–macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med. 1991, 324: 1464-1470. 10.1056/NEJM199105233242104.CrossRefPubMed

16.

Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO: Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci U S A. 1990, 87: 1913-1916. 10.1073/pnas.87.5.1913.CrossRefPubMedPubMedCentral

17.

Beutler E, Kay A, Saven A, Garver P, Thurston D, Dawson A, Rosenbloom B: Enzyme replacement therapy for Gaucher disease. Blood. 1991, 78: 1183-1189.PubMed

18.

Figueroa ML, Rosenbloom BE, Kay AC, Garver P, Thurston DW, Koziol JA, Gelbart T, Beutler E: A less costly regimen of alglucerase to treat Gaucher’s disease. N Engl J Med. 1992, 327: 1632-1636. 10.1056/NEJM199212033272304.CrossRefPubMed

19.

Hollak CE, Aerts JM, Goudsmit R, Phoa SS, Ek M, van Weely S, von dem Borne AE, van Oers MH: Individualised low-dose alglucerase therapy for type 1 Gaucher’s disease. Lancet. 1995, 345: 1474-1478. 10.1016/S0140-6736(95)91037-9.CrossRefPubMed

20.

Pastores GM, Sibille AR, Grabowski GA: Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood. 1993, 82: 408-416.PubMed

21.

Zimran A, Kay A, Gelbart T, Garver P, Thurston D, Saven A, Beutler E: Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore). 1992, 71: 337-353. 10.1097/00005792-199211000-00002.CrossRef

22.

de Fost M, van Noesel CJ, Aerts JM, Maas M, Poll RG, Hollak CE: Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy. Haematologica. 2008, 93: 1119-1120. 10.3324/haematol.12651.CrossRefPubMed

23.

Damiano AM, Pastores GM, Ware JE: The health-related quality of life of adults with Gaucher’s disease receiving enzyme replacement therapy: results from a retrospective study. Qual Life Res. 1998, 7: 373-386. 10.1023/A:1008814105603.CrossRefPubMed

24.

Giraldo P, Solano V, Perez-Calvo JI, Giralt M, Rubio-Felix D: Quality of life related to type 1 Gaucher disease: Spanish experience. Qual Life Res. 2005, 14: 453-462. 10.1007/s11136-004-0794-y.CrossRefPubMed

25.

Hayes RP, Grinzaid KA, Duffey EB, Elsas LJ: The impact of Gaucher disease and its treatment on quality of life. Qual Life Res. 1998, 7: 521-534. 10.1023/A:1008878425167.CrossRefPubMed

26.

Masek BJ, Sims KB, Bove CM, Korson MS, Short P, Norman DK: Quality of life assessment in adults with type 1 Gaucher disease. Qual Life Res. 1999, 8: 263-268. 10.1023/A:1008859420641.CrossRefPubMed

27.

Weinreb N, Barranger J, Packman S, Prakash-Cheng A, Rosenbloom B, Sims K, Angell J, Skrinar A, Pastores GM: Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet. 2007, 71: 576-588. 10.1111/j.1399-0004.2007.00811.x.CrossRefPubMed

28.

Connock M, Burls A, Frew E, Fry-Smith A, Juarez-Garcia A, McCabe C, Wailoo A, Abrams K, Cooper N, Sutton A, O’Hagan A, Moore D: The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher’s disease: a systematic review. Health Technol Assess. 2006, 10: iii-136.

29.

Taddei TH, Kacena KA, Yang M, Yang R, Malhotra A, Boxer M, Aleck KA, Rennert G, Pastores GM, Mistry PK: The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol. 2009, 84: 208-214. 10.1002/ajh.21362.CrossRefPubMedPubMedCentral

30.

van Dussen L, Biegstraaten M, Hollak CE, Dijkgraaf MG: Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease. Orphanet J Rare Dis. 2014, 9: 51-10.1186/1750-1172-9-51.CrossRefPubMedPubMedCentral

31.

Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA: The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011, 117: 4190-4207. 10.1182/blood-2010-08-302984.CrossRefPubMed

32.

Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M, Grabowski GA, Mistry PK, Tylki-Szymanska A: Therapeutic goals in the treatment of Gaucher disease. Semin Hematol. 2004, 41: 4-14. 10.1053/j.seminhematol.2004.07.009.CrossRefPubMed

33.

Ludbrook J, Royse AG: Analysing clinical studies: principles, practice and pitfalls of Kaplan-Meier plots. ANZ J Surg. 2008, 78: 204-210. 10.1111/j.1445-2197.2007.04405.x.CrossRefPubMed

34.

Boomsma JM, van Dussen L, Wiersma MG, Groener JE, Aerts JM, Maas M, Hollak CE: Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study. Blood Cells Mol Dis. 2010, 44: 181-187. 10.1016/j.bcmd.2009.12.006.CrossRefPubMed

35.

Krasnewich D, Dietrich K, Bauer L, Ginns EI, Sidransky E, Hill S: Splenectomy in Gaucher disease: new management dilemmas. Blood. 1998, 91: 3085-3087.PubMed

36.

Ponce E, Moskovitz J, Grabowski G: Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase. Blood. 1997, 90: 43-48.PubMed

37.

Rosenthal DI, Doppelt SH, Mankin HJ, Dambrosia JM, Xavier RJ, McKusick KA, Rosen BR, Baker J, Niklason LT, Hill SC: Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics. 1995, 96: 629-637.PubMed

38.

Hollak C, Maas M, Akkerman E, den Heeten A, Aerts H: Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol Dis. 2001, 27: 1005-1012. 10.1006/bcmd.2001.0474.CrossRefPubMed

39.

Maas M, Hollak CE, Akkerman EM, Aerts JM, Stoker J, den Heeten GJ: Quantification of skeletal involvement in adults with type I Gaucher’s disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. AJR Am J Roentgenol. 2002, 179: 961-965. 10.2214/ajr.179.4.1790961.CrossRefPubMed

40.

Poll LW, Koch JA, vom Dahl S, Willers R, Scherer A, Boerner D, Niederau C, Haussinger D, Modder U: Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results. Skeletal Radiol. 2001, 30: 496-503. 10.1007/s002560100375.CrossRefPubMed

41.

Maas M, van Kuijk C, Stoker J, Hollak CE, Akkerman EM, Aerts JF, den Heeten GJ: Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging–initial experience. Radiology. 2003, 229: 554-561. 10.1148/radiol.2292020296.CrossRefPubMed

42.

Bembi B, Ciana G, Mengel E, Terk MR, Martini C, Wenstrup RJ: Bone complications in children with Gaucher disease. Br J Radiol. 2002, 75 (Suppl 1): A37-A44. 10.1259/bjr.75.suppl_1.750037.CrossRefPubMed

43.

Ciana G, Addobbati R, Tamaro G, Leopaldi A, Nevyjel M, Ronfani L, Vidoni L, Pittis MG, Bembi B: Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J Inherit Metab Dis. 2005, 28: 723-732. 10.1007/s10545-005-0032-y.CrossRefPubMed

44.

Schiffmann R, Mankin H, Dambrosia JM, Xavier RJ, Kreps C, Hill SC, Barton NW, Rosenthal DI: Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis. 2002, 28: 288-296. 10.1006/bcmd.2002.0517.CrossRefPubMed

45.

Sims KB, Pastores GM, Weinreb NJ, Barranger J, Rosenbloom BE, Packman S, Kaplan P, Mankin H, Xavier R, Angell J, Fitzpatrick MA, Rosenthal D: Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet. 2008, 73: 430-440. 10.1111/j.1399-0004.2008.00978.x.CrossRefPubMedPubMedCentral

46.

van Dussen L, Maas M, Hangartner TN: Imaging Skeletal Involvement in Gaucher Disease. In Advances in Gaucher Disease: Basic and Clinical Perspectives. Future Medicine Ltd; 2013:182–200.CrossRef

47.

Hollak CE, de Fost M, Aerts JM, vom Dahl S: Low-dose versus high-dose therapy for gaucher disease: goals and markers. Blood. 2007, 109: 387-388. 10.1182/blood-2006-07-033233.CrossRefPubMed

48.

Belmatoug N, de Villemeur TB: Skeletal response to enzyme replacement therapy for type I gaucher disease: a preliminary report of the french experience. Semin Hematol. 1995, 32: 33-38.

49.

Deegan PB, Pavlova E, Tindall J, Stein PE, Bearcroft P, Mehta A, Hughes D, Wraith JE, Cox TM: Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine (Baltimore). 2011, 90: 52-60. 10.1097/MD.0b013e3182057be4.CrossRef

50.

El-Beshlawy A, Ragab L, Youssry I, Yakout K, El-Kiki H, Eid K, Mansour IM, Abd El-Hamid S, Yang M, Mistry PK: Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients. J Inherit Metab Dis. 2006, 29: 92-98. 10.1007/s10545-006-0121-6.CrossRefPubMed

51.

Elstein D, Hadas-Halpern I, Itzchaki M, Lahad A, Abrahamov A, Zimran A: Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement. Blood Cells Mol Dis. 1996, 22: 104-111. 10.1006/bcmd.1996.0016.CrossRefPubMed

52.

Stirnemann J, Belmatoug N, Vincent C, Fain O, Fantin B, Mentre F: Bone events and evolution of biologic markers in Gaucher disease before and during treatment. Arthritis Res Ther. 2010, 12: R156-10.1186/ar3111.CrossRefPubMedPubMedCentral

53.

Charrow J, Dulisse B, Grabowski GA, Weinreb NJ: The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet. 2007, 71: 205-211. 10.1111/j.1399-0004.2007.00769.x.CrossRefPubMed

54.

Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Zimran A: Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med. 2002, 113: 112-119. 10.1016/S0002-9343(02)01150-6.CrossRefPubMed

55.

Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ: Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. Br J Haematol. 2009, 147: 561-570. 10.1111/j.1365-2141.2009.07872.x.CrossRefPubMedPubMedCentral

56.

Lee RE: The pathology of Gaucher disease. Prog Clin Biol Res. 1982, 95: 177-217.PubMed

57.

Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ: A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002, 346: 564-569. 10.1056/NEJMoa01133202.CrossRefPubMed

58.

Brady K, Corash L, Bhargava V: Multiple myeloma arising from monoclonal gammopathy of undetermined significance in a patient with Gaucher’s disease. Arch Pathol Lab Med. 1997, 121: 1108-1111.PubMed

59.

Weinreb NJ, Lee RE: Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher Disease who were never treated with enzyme replacement therapy. Crit Rev Oncog. 2013, 18: 177-195. 10.1615/CritRevOncog.2013005921.CrossRefPubMed

60.

de Fost M, Hollak CE, Groener JE, Aerts JM, Maas M, Poll LW, Wiersma MG, Haussinger D, Brett S, Brill N, vom Dahl S: Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood. 2006, 108: 830-835. 10.1182/blood-2005-12-5072.CrossRefPubMed

61.

Grabowski GA, Kacena K, Cole JA, Hollak CE, Zhang L, Yee J, Mistry PK, Zimran A, Charrow J, vom Dahl S: Dose–response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet Med. 2009, 11: 92-100. 10.1097/GIM.0b013e31818e2c19.CrossRefPubMedPubMedCentral

Title: Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications
Authors: Laura van Dussen
Marieke Biegstraaten
Marcel GW Dijkgraaf
Carla EM Hollak
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Orphanet Journal of Rare Diseases / Issue 1/2014
Electronic ISSN: 1750-1172
DOI: https://doi.org/10.1186/s13023-014-0112-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

A systematic review of the prevalence of Morquio A syndrome: challenges for study reporting in rare diseases

Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset fabry mutation (IVS4 + 919G > A)

Treatment of motor and behavioural symptoms in three Lesch-Nyhan patients with intrathecal baclofen

Lack of synergistic effect of resveratrol and sigma-1 receptor agonist (PRE-084) in SOD1G93A ALS mice: overlapping effects or limited therapeutic opportunity?

LC3, an autophagosome marker, is expressed on oligodendrocytes in Nasu-Hakola disease brains

Cryptogenic stroke and small fiber neuropathy of unknown etiology in patients with alpha-galactosidase A-10T genotype